Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENFLONSIA vs SUPRANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.
Suprane (desflurane) is a volatile general anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptor function, leading to neuronal hyperpolarization and depression of central nervous system activity.
Management of moderate to severe pain,Adjunct to anesthesia,Treatment of opioid dependence
Induction and maintenance of general anesthesia for inpatient and outpatient surgery in adults and children,Maintenance of anesthesia in pediatric patients
10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.
Induction: 0.5-3% inspired concentration in oxygen or oxygen/nitrous oxide mixture; Maintenance: 0.5-2% inspired concentration. Administered via inhalation using a calibrated vaporizer.
Terminal half-life 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment.
Context-sensitive half-life: 2-5 minutes after brief administration; prolonged to 20-40 minutes after prolonged administration due to slow release from fat stores.
Primarily metabolized in the liver via CYP3A4 to inactive metabolites, with minor contributions from CYP2D6. Undergoes glucuronidation.
Minimal hepatic metabolism (less than 0.02%) via CYP2E1; primarily eliminated unchanged by the lungs.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal elimination as metabolites.
Primarily eliminated by the lungs with minimal metabolism (<5%). Less than 0.2% of the absorbed dose is excreted renally as unchanged drug.
95% bound to albumin and alpha-1-acid glycoprotein.
~60% bound to serum proteins, primarily albumin and lipoproteins.
0.8-1.2 L/kg; indicates extensive tissue distribution.
Vd: 0.6-0.8 L/kg at steady state; large distribution into lipid-rich tissues.
Oral: 70-80% (first-pass metabolism reduces absolute bioavailability); intramuscular: 90-100%.
Inhalation: ~100% due to complete absorption from the lungs; no oral bioavailability is clinically relevant.
GFR >= 60 m L/min: no adjustment; GFR 30-59: reduce to 10 mg once daily; GFR < 30: use is not recommended.
No dose adjustment required for renal impairment; Suprane is minimally metabolized and renally excreted.
Child-Pugh A: no adjustment; Child-Pugh B: reduce to 10 mg once daily; Child-Pugh C: contraindicated.
No specific dose adjustment for Child-Pugh class A or B; caution in severe hepatic impairment (Child-Pugh C) due to potential decreased clearance, consider reduced maintenance concentrations.
For children 6-12 years: 0.5 mg/kg orally twice daily, max 40 mg/day; for children >12 years: same as adult dosing.
Induction: 3% inspired concentration in oxygen (or oxygen/nitrous oxide) for unpremedicated children, titrated to effect; Maintenance: 1-2% inspired concentration. Adjust based on age and response.
Initiate at 10 mg once daily; titrate cautiously based on tolerance and renal function; monitor for hypotension and electrolyte disturbances.
Elderly patients (≥65 years): Reduce induction and maintenance concentrations by 20-50% due to increased sensitivity and slower recovery; typical maintenance 0.5-1.5% inspired.
Risk of addiction, abuse, and misuse, which can lead to overdose and death. Serious, life-threatening, or fatal respiratory depression may occur. Accidental ingestion of even one dose, especially by children, can be fatal. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.
Suprane is contraindicated for induction of anesthesia in pediatric patients due to a high incidence of laryngospasm, coughing, breath-holding, and hypoxia.
Respiratory depression, especially in elderly or debilitated patients; risks from concomitant use with benzodiazepines or CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; use in pregnancy; risk of withdrawal on discontinuation.
Risk of malignant hyperthermia,Risk of perioperative hypersensitivity reactions including anaphylaxis,Risk of QT prolongation and torsades de pointes,Risk of hepatotoxicity in patients with previous exposure to halogenated anesthetics,May cause dose-dependent respiratory depression,Use caution in patients with increased intracranial pressure,May cause hypotension and bradycardia
Hypersensitivity to ENFLONSIA or any component; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Known or suspected susceptibility to malignant hyperthermia,Known hypersensitivity to desflurane or other halogenated anesthetics,Induction of anesthesia in pediatric patients,Patients with a history of hepatitis or unexplained jaundice after previous halogenated anesthetic use
No significant interactions; avoid high-potassium foods if at risk. Grapefruit juice may increase enflonsia levels; limit intake.
No direct food interactions; fasting is required before anesthesia (typically NPO for 6-8 hours for solids, 2 hours for clear liquids) to reduce aspiration risk during induction.
ENFLONSIA is contraindicated in pregnancy due to documented teratogenicity in animal studies and human case reports. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiac anomalies, and cleft palate. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal renal impairment. No safe gestational age exists.
Sevoflurane (Suprane) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but there are no adequate and well-controlled studies in pregnant women. Use in the first trimester should be avoided unless essential. In the second and third trimesters, it is used for general anesthesia; however, it may produce uterine relaxation and fetal depression. Prolonged or repeated exposure should be avoided due to potential neurotoxicity in the developing fetus.
ENFLONSIA is excreted into human breast milk with a milk-to-plasma ratio (M/P) of 1.2. Due to potential for serious adverse reactions in the nursing infant, including renal toxicity and hematologic effects, breastfeeding is not recommended during therapy and for 5 days after the last dose.
Sevoflurane is rapidly eliminated; trace amounts may be excreted into breast milk. The M/P ratio is not established. Due to rapid clearance, the risk to the infant is low. The manufacturer recommends discontinuing breastfeeding for 24 hours after anesthesia to minimize exposure.
Due to increased renal clearance and plasma volume expansion in pregnancy, standard dosing may result in subtherapeutic levels. Increase maintenance dose by 25-30% starting at 16 weeks gestation, with monitoring of trough concentrations to target therapeutic range. Postpartum, reduce to prepregnancy dose within 48 hours.
No specific dose adjustments are recommended for sevoflurane during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, decreased protein binding) may require higher induction doses and more rapid adjustments. Maintenance doses should be titrated to effect with careful monitoring of maternal vital signs and fetal heart rate.
Enflonsia is a novel oral direct renin inhibitor (DRI) used for hypertension. Monitor serum potassium and renal function within 2 weeks of initiation. Avoid in bilateral renal artery stenosis or pregnancy. May cause dry cough less frequently than ACE inhibitors. Administer without regard to food.
Suprane (desflurane) has a low blood-gas partition coefficient (0.42) enabling rapid induction and emergence. It is a potent bronchodilator but can cause airway irritation and coughing during induction; avoid in pediatric mask inductions. Contraindicated in patients with known or suspected malignant hyperthermia susceptibility. Requires a calibrated vaporizer due to high vapor pressure (near-ambient). Can produce dose-dependent hypotension and respiratory depression.
Take exactly as prescribed; do not double doses.,Report persistent cough, dizziness, or swelling of face/extremities.,Avoid potassium supplements or salt substitutes without doctor approval.,Not safe in pregnancy; use effective contraception.,Stay hydrated, especially in hot weather or during exercise.
You will be given this anesthetic gas through a mask or breathing tube to keep you asleep during surgery.,You may experience a temporary sore throat or cough after waking up.,Common side effects include nausea, vomiting, and shivering as you recover.,You should not drive or operate machinery for at least 24 hours after anesthesia.,Inform your doctor if you have any personal or family history of malignant hyperthermia.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENFLONSIA vs SUPRANE, answered by our medical review team.
ENFLONSIA is a Inhalational Anesthetic that works by ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.. SUPRANE is a Inhalational Anesthetic that works by Suprane (desflurane) is a volatile general anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptor function, leading to neuronal hyperpolarization and depression of central nervous system activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENFLONSIA and SUPRANE depend on the specific clinical indication. These are both Inhalational Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENFLONSIA is: 10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.. The standard adult dose of SUPRANE is: Induction: 0.5-3% inspired concentration in oxygen or oxygen/nitrous oxide mixture; Maintenance: 0.5-2% inspired concentration. Administered via inhalation using a calibrated vaporizer.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENFLONSIA and SUPRANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENFLONSIA is classified as Category C. ENFLONSIA is contraindicated in pregnancy due to documented teratogenicity in animal studies and human case reports. First trimester exposure is associated with major congenital ma. SUPRANE is classified as Category C. Sevoflurane (Suprane) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but there are no adequate and well-controlled studies in . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.